Literature DB >> 30232408

Klotho suppresses colorectal cancer through modulation of the unfolded protein response.

Tammi Arbel Rubinstein1,2, Shiri Shahmoon1,2, Ehud Zigmond2,3, Tal Etan1,2, Keren Merenbakh-Lamin1, Metsada Pasmanik-Chor4, Gil Har-Zahav5,6, Iris Barshack2,7, Gilad W Vainer8, Nir Skalka2, Rina Rosin-Arbesfeld2, Chen Varol3,9, Tami Rubinek1,2, Ido Wolf10,11.   

Abstract

Klotho is an anti-aging transmembrane protein, which can be shed and function as a hormone. Accumulating data indicate klotho as a tumor suppressor in a wide array of malignancies and indicate the subdomain KL1 as the active region of the protein. We aimed to study the role of klotho as a tumor suppressor in colorectal cancer. Bioinformatics analyses of TCGA datasets indicated reduced klotho mRNA levels in human colorectal cancer, along with negative regulation of klotho expression by hypermethylation of the promoter and 1st exon, and hypomethylation of an area within the gene. Overexpression or treatment with klotho or KL1 inhibited proliferation of colorectal cancer cells in vitro. The in vivo activity of klotho and KL1 was examined using two models recapitulating development of tumors in the normal colonic environment of immune-competent mice. Treatment with klotho inhibited formation of colon polyps induced by the carcinogen azoxymethane, and KL1 treatment slowed growth of orthotopically-implanted colorectal tumors. Gene expression array revealed that klotho and KL1 expression enhanced the unfolded protein response (UPR) and this was further established by increased levels of spliced XBP1, GRP78 and phosphorylated-eIF2α. Furthermore, attenuation of the UPR partially abrogated klotho tumor suppressor activity. In conclusion, this study indicates klotho as a tumor suppressor in colorectal cancer and identifies, for the first time, the UPR as a pathway mediating klotho activities in cancer. These data suggest that administration of exogenous klotho or KL1 may serve as a novel strategy for prevention and treatment of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30232408     DOI: 10.1038/s41388-018-0489-4

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  Suppression of aberrant transient receptor potential cation channel, subfamily V, member 6 expression in hyperproliferative colonic crypts by dietary calcium.

Authors:  Sara Peleg; Joseph H Sellin; Yu Wang; Michael R Freeman; Shahid Umar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-05-27       Impact factor: 4.052

2.  Transient mammalian cell transfection with polyethylenimine (PEI).

Authors:  Patti A Longo; Jennifer M Kavran; Min-Sung Kim; Daniel J Leahy
Journal:  Methods Enzymol       Date:  2013       Impact factor: 1.600

3.  Ameliorating effect of Klotho on endoplasmic reticulum stress and renal fibrosis induced by unilateral ureteral obstruction.

Authors:  Qi-Feng Liu; Jian-Ming Ye; Zhi-Yong Deng; Li-Xia Yu; Qiang Sun; Sha-Sha Li
Journal:  Iran J Kidney Dis       Date:  2015-07       Impact factor: 0.892

4.  Carboxypeptidase E: a negative regulator of the canonical Wnt signaling pathway.

Authors:  N Skalka; M Caspi; E Caspi; Y P Loh; R Rosin-Arbesfeld
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 9.867

Review 5.  The impact of the endoplasmic reticulum protein-folding environment on cancer development.

Authors:  Miao Wang; Randal J Kaufman
Journal:  Nat Rev Cancer       Date:  2014-09       Impact factor: 60.716

6.  Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.

Authors:  P J Morin; A B Sparks; V Korinek; N Barker; H Clevers; B Vogelstein; K W Kinzler
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

Review 7.  Klotho acts as a tumor suppressor in cancers.

Authors:  Biao Xie; Jinhui Chen; Bin Liu; Junkun Zhan
Journal:  Pathol Oncol Res       Date:  2013-07-05       Impact factor: 3.201

8.  Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling.

Authors:  V Zismanov; M Lishner; S Tartakover-Matalon; J Radnay; H Shapiro; L Drucker
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

Review 9.  The Role of Alpha-Klotho as a Universal Tumor Suppressor.

Authors:  T Rubinek; I Wolf
Journal:  Vitam Horm       Date:  2016-04-06       Impact factor: 3.421

10.  Overexpression of Klotho suppresses liver cancer progression and induces cell apoptosis by negatively regulating wnt/β-catenin signaling pathway.

Authors:  Huidong Sun; Yanchao Gao; Kemei Lu; Guimei Zhao; Xuehua Li; Zhu Li; Hong Chang
Journal:  World J Surg Oncol       Date:  2015-10-24       Impact factor: 2.754

View more
  16 in total

1.  β-Klotho inhibits CSF-1 secretion and delays the development of endometrial cancer.

Authors:  Fu Hua; Xiaogang Chen
Journal:  Cell Cycle       Date:  2022-06-28       Impact factor: 5.173

Review 2.  The role of α-klotho in human cancer: molecular and clinical aspects.

Authors:  Hagai Ligumsky; Keren Merenbakh-Lamin; Noa Keren-Khadmy; Ido Wolf; Tami Rubinek
Journal:  Oncogene       Date:  2022-08-29       Impact factor: 8.756

3.  Klotho rewires cellular metabolism of breast cancer cells through alteration of calcium shuttling and mitochondrial activity.

Authors:  Riva Shmulevich; Tsipi Ben-Kasus Nissim; Ido Wolf; Keren Merenbakh-Lamin; Daniel Fishman; Israel Sekler; Tami Rubinek
Journal:  Oncogene       Date:  2020-05-12       Impact factor: 9.867

4.  High expression of TREM2 promotes EMT via the PI3K/AKT pathway in gastric cancer: bioinformatics analysis and experimental verification.

Authors:  Chunmei Li; Xiaoming Hou; Shuqiao Yuan; Yigan Zhang; Wenzhen Yuan; Xiaoguang Liu; Juan Li; Yuping Wang; Quanlin Guan; Yongning Zhou
Journal:  J Cancer       Date:  2021-04-02       Impact factor: 4.207

Review 5.  Klotho and the Treatment of Human Malignancies.

Authors:  Aishani Sachdeva; Jerome Gouge; Christos Kontovounisios; Stella Nikolaou; Alan Ashworth; Kenneth Lim; Irene Chong
Journal:  Cancers (Basel)       Date:  2020-06-23       Impact factor: 6.639

6.  Establishing and Validating an Aging-Related Prognostic Four-Gene Signature in Colon Adenocarcinoma.

Authors:  Lian Zheng; Yang Yang; Xiaorong Cui
Journal:  Biomed Res Int       Date:  2021-11-08       Impact factor: 3.411

7.  Klotho Inhibits Proliferation in a RET Fusion Model of Papillary Thyroid Cancer by Regulating the Wnt/β-Catenin Pathway.

Authors:  Qiong Wu; Liang Jiang; Jiang Wu; HaiFang Dong; Yaping Zhao
Journal:  Cancer Manag Res       Date:  2021-06-17       Impact factor: 3.989

8.  Towards Age-Related Anti-Inflammatory Therapy: Klotho Suppresses Activation of ER and Golgi Stress Response in Senescent Monocytes.

Authors:  Jennifer Mytych; Przemysław Sołek; Agnieszka Będzińska; Kinga Rusinek; Aleksandra Warzybok; Anna Tabęcka-Łonczyńska; Marek Koziorowski
Journal:  Cells       Date:  2020-01-21       Impact factor: 6.600

9.  Klotho-mediated targeting of CCL2 suppresses the induction of colorectal cancer progression by stromal cell senescent microenvironments.

Authors:  Yangyang Liu; Jie Pan; Xia Pan; Lunpo Wu; Jun Bian; Zhenghua Lin; Meng Xue; Tingting Su; Sanchuan Lai; Fei Chen; Qiwei Ge; Luyi Chen; Shufang Ye; Yabi Zhu; Shujie Chen; Liangjing Wang
Journal:  Mol Oncol       Date:  2019-10-06       Impact factor: 6.603

10.  A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy.

Authors:  Tammi Arbel Rubinstein; Inbal Reuveni; Arkadi Hesin; Anat Klein-Goldberg; Hannes Olauson; Tobias E Larsson; Carmela R Abraham; Ella Zeldich; Assumpció Bosch; Miguel Chillón; Kenneth Samuel Hollander; Ayelet Shabtay-Orbach; Gilad W Vainer; Ido Wolf; Tami Rubinek
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.